SPRB (sprucebiosciences.com) Earnings growth in current year

Spruce Biosciences (SPRB) operates in a defensive sector where demand for the treatment of endocrine pathologies remains independent of economic cycles. High barriers to entry and orphan drug status provide the company with exclusivity, as evidenced by the annual net income per share dynamics, where the indicator value reaches 42.50. Management is currently optimizing the pipeline in an effort to restore investor confidence following controversial tests.

SPRB: Spruce Biosciences Earnings per share growth in current year 07/04/2022 - 11/13/2026

Financial and market metric breakdowns for Spruce Biosciences (SPRB)

- share price and expert price forecast:

Price Spruce Biosciences Inc.|SPRB - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Spruce Biosciences, Inc.|SPRB - Enterprise Value

- book capitalization data:

Net Assets per Single Share Spruce Biosciences|SPRB - Company Book Value|Market-to-Book Ratio sprucebiosciences.com|SPRB - Aggregate Company Assets

- debt burden and liquidity indicators:

- earnings and valuation multiples information:

SPRB - Company Net Income|Forward Earnings Spruce Biosciences|SPRB - Price to Earnings Ratio|Future Price to Earnings Multiple Spruce Biosciences Inc.|SPRB - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Spruce Biosciences, Inc.|SPRB - Operating profit EBITDA|Net earnings per share for the last 12 months Spruce Biosciences|SPRB - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months sprucebiosciences.com|SPRB - Net earnings per share growth this year|Expected earnings per share trend next year Spruce Biosciences

- revenue and sales proceeds data:

SPRB - Revenue and Sales Volume|Company Projected Revenue sprucebiosciences.com|SPRB - P/S Multiple|Market Cap to Expected Sales Ratio Spruce Biosciences, Inc.

Basic company analysis:SPRB - Spruce Biosciences Inc.

Spruce Biosciences focuses on developing therapies for rare endocrine pathologies, making earnings per share a key indicator of R&D investment efficiency. This metric measures annual profit dynamics, allowing for an assessment of business scaling rates relative to the previous period. Analyzing the annual EPS growth trajectory helps determine the resilience of the company's capitalization to industry risks and confirms the fundamental value of its assets.

Main competitors